Andreas Klosterman, Ph.D. (CSO) will give an update on selectION’s best-in-class ion channel antagonists and discuss the principles of the company’s systematical peptide design to obtain the most selective and specific ion channel blockers.
- Meet selectION Inc. at Biocom’s 10th Annual Global Life Science Partnering Conference in San Diego on February 25th to 27th, 2020
- selectION, Inc. Announces $4.1M Series A Investment
- selectION, Inc. Strengthens Scientific Advisory Team with the Appointment of Fred Ramsdell, Ph.D. & Mark Benedyk, Ph.D. as Strategic Advisors and Members of the Scientific Advisory Board